AA
RYTM icon

AlphaCentric Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

AlphaCentric Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$809K Buy
9,297
+4,245
+84% +$413K 0.81% 28
2025
Q4 		$541K Buy
+5,052
New +$536K 0.54% 58

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AlphaCentric Advisors's RYTM Position: Q1 2026 in Review

AlphaCentric Advisors increased its Rhythm Pharmaceuticals (RYTM) stake by 84% in Q1 2026, buying an estimated $413K and bringing the position to 9,297 shares worth $809K. The position accounts for 0.81% of the portfolio, ranked #28.

AlphaCentric Advisors first reported a position in RYTM in Q4 2025 and has held it in 2 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • AlphaCentric Advisors held 9,297 shares of Rhythm Pharmaceuticals worth $809K as of Q1 2026.
  • AlphaCentric Advisors bought 4,245 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $413K.
  • Rhythm Pharmaceuticals made up 0.81% of AlphaCentric Advisors's portfolio in Q1 2026, its #28 holding.
  • AlphaCentric Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.